Maze Therapeutics, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
Misbah Tahir, the Company’s Chief Financial Officer, will be designated principal accounting officer following Ms. Bachrodt’s departure.
On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026.
Extracted from this filing and checked against the source text.
Misbah Tahir changed role as Chief Financial Officer and principal accounting officer at Maze Therapeutics, Inc..
Misbah Tahir, the Company’s Chief Financial Officer, will be designated principal accounting officer following Ms. Bachrodt’s departure.View on SEC.gov
Amy Bachrodt departed as Senior Vice President, Finance at Maze Therapeutics, Inc..
On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.